{"CAPTION FIG1.png": "'Figure 1: **Crystal structure of human**\\\\({}_{\\\\rm CD}\\\\)**EFhd2. (a) Schematic of human \\\\({}_{\\\\rm CD}\\\\)EFhd2; PxxP: proline-rich region, EF: EF-hands, LM: ligand mimic, CC: coiled-coil, ABS: actin-binding site. (b) Stereowiew of the \\\\({}_{\\\\rm CD}\\\\)EFhd2 structure. The colour coding used is the same as in (a). Silver spheres indicate two Ca\\\\({}^{2+}\\\\) ions located near the loops between the EF-hand motifs. (c) Hydrophobic interactions and hydrogen bonds between the PxxP motif and the EF-hand domain. Phe80, Pro82, Phe86 and Phe89 in the PxxP motif are proximal to Phe150, Leu154 and Leu155 in helix 4. Tyr83, Glu85 and Glu88 in the PxxP motif form hydrogen bonds with Lys95 in helix 1 (H1), and Arg151 and Arg158 in helix 4 (H4). (d) Intramolecular interactions between hydrophobic residues of the EF-hand domains and the LM-helix.\\n\\n'", "CAPTION FIG2.png": "'Figure 2: **Structure comparison between Ca\\\\({}^{2+}\\\\)-bound\\\\({}_{\\\\mathrm{c}\\\\mathrm{D}}\\\\)EFhd2 (green), cm\\\\({}^{2}\\\\)EFhd2EF1 (cyan) and cm\\\\({}^{2}\\\\)EFhd2EF2 (orange).** (a) Structural superposition of Ca\\\\({}^{2+}\\\\)-bound\\\\({}_{\\\\mathrm{c}\\\\mathrm{D}}\\\\)EFhd2 (green), cm\\\\({}^{2}\\\\)EFhd2EF1 (cyan), and cm\\\\({}^{2}\\\\)EFhd2EF2 (orange). (b) The Ca\\\\({}^{2+}\\\\)-binding loop of EF1 of Ca\\\\({}^{2+}\\\\)-bound\\\\({}_{\\\\mathrm{c}\\\\mathrm{D}}\\\\)EFhd2 (green) and cm\\\\({}^{2}\\\\)EFhd2EF1 (cyan). (c) Ca\\\\({}^{2+}\\\\)-binding loop of EF2 of Ca\\\\({}^{2+}\\\\)-bound\\\\({}_{\\\\mathrm{c}\\\\mathrm{D}}\\\\)EFhd2 (green) and cm\\\\({}^{2}\\\\)EFhd2EF2 (orange). (d) Plot of the crystallographic B-factor per residue of Ca\\\\({}^{2+}\\\\)-bound\\\\({}_{\\\\mathrm{c}\\\\mathrm{D}}\\\\)EFhd2 (20.4 \u00c5\\\\({}^{2}\\\\), green), cm\\\\({}^{2}\\\\)EFhd2EF1 (35.6 \u00c5\\\\({}^{2}\\\\), cyan) and cm\\\\({}^{2}\\\\)EFhd2EF2 (21.5 \u00c5\\\\({}^{2}\\\\), orange). The disordered region of the PxxP motif in the crystal structure of cm\\\\({}^{2}\\\\)EFhd2 is shown by the blue dashed line.\\n\\n'", "CAPTION FIG3.png": "'Figure 3: **Structural comparison of ensemble models of \\\\(\\\\mathbf{c_{\\\\mathrm{D}}}\\\\)EFhd2, \\\\(\\\\mathbf{c_{\\\\mathrm{D}}}\\\\)EFhd2F1 and \\\\(\\\\mathbf{c_{\\\\mathrm{D}}}\\\\)EFhd2F2. Ensemble models of (a) Ca\\\\({}^{1+}\\\\)-bound \\\\(\\\\mathbf{c_{\\\\mathrm{D}}}\\\\)EFhd2, (b) \\\\(\\\\mathbf{c_{\\\\mathrm{D}}}\\\\)EFhd2F1 and (c) \\\\(\\\\mathbf{c_{\\\\mathrm{D}}}\\\\)EFhd2F1. Structures coloured by B-factor. The B-factors are coloured from a blue/thin line to a red/thicker line with increasing B-factor. (d) The root-mean-square fluctuation (RMSF) of ensemble models for Ca\\\\({}^{2+}\\\\)-bound \\\\(\\\\mathbf{c_{\\\\mathrm{D}}}\\\\)EFhd2 (green), \\\\(\\\\mathbf{c_{\\\\mathrm{D}}}\\\\)EFhd2F1 (cyan) and \\\\(\\\\mathbf{c_{\\\\mathrm{D}}}\\\\)EFhd2F2 (orange). RMSF in the EF1 of \\\\(\\\\mathbf{c_{\\\\mathrm{D}}}\\\\)EFhd2F1 is consistent with the crystallographic B-factor. The disordered region of the PxxP motif in the crystal structure of \\\\(\\\\mathbf{c_{\\\\mathrm{D}}}\\\\)EFhd2 is shown by the blue dashed line.**\\n\\n'", "CAPTION FIG4.png": "'Figure 4: **Ca\\\\({}^{2+}\\\\)-binding properties of EFhd2.** (**a**) ITC data for EFhd2 with Ca\\\\({}^{2+}\\\\). Each experiment was repeated in triplicate. (**b**) Light scattering intensity at 470 nm and various temperatures for thermal aggregation of \\\\({}_{\\\\mathrm{CD}}\\\\)EFhd2 (green), \\\\({}_{\\\\mathrm{CD}}\\\\)EFhd2\\\\({}^{\\\\mathrm{EF1}}\\\\) (cyan) and \\\\({}_{\\\\mathrm{CD}}\\\\)EFhd2\\\\({}^{\\\\mathrm{EF2}}\\\\) (orange). The protein concentration was 250 \\\\(\\\\mu\\\\)M. Each experiment was repeated in triplicate. A reduction in intensity at high temperatures indicates precipitation of large-sized aggregates [70].\\n\\n'", "CAPTION FIG5.png": "'\\n\\n**Figure 5.** **In vitro co-sedimentation (F-actin binding) assay and low-speed F-actin bundling assay.** (**a**) Co-sedimentation assay and \\\\(\\\\langle\\\\mathbf{b}\\\\rangle\\\\) low-speed actin-bundling assay of EFhd2 (full-length) and its mutants. Protein samples (5 \\\\(\\\\mu\\\\)M) were added to pre-polymerised actin (2 \\\\(\\\\mu\\\\)M) in the presence of 1 mM CaCl2. RSA and \\\\(\\\\alpha\\\\)-actinin were used as a negative and positive control, respectively. The percentage of actin distribution was quantified and is presented in the bar graphs. Each experiment was repeated in triplicate.\\n\\n'", "CAPTION FIG6.png": "'Figure 6: **Schematic of the actin-bundling activity of EFhd2.** (**a**) SDS-PAGE analysis of the two engineered Cys mutants of the coiled-coil (residues 199\u2013240). Protein samples were analysed under reducing or non-reducing conditions. (**b**) Schematic of the Ca\\\\({}^{2+}\\\\)-dependent F-actin bundling mechanism of EFhd2 (ABS: actin-binding site).\\n\\n'", "CAPTION TAB1.png": "'\\n\\n\\\\begin{table}\\n\\\\begin{tabular}{l l} \\\\hline \\\\hline \\\\multicolumn{1}{c}{**Table 1.** **Data collection and refinement statistics.** \\\\({}^{\\\\rm a}\\\\)Beamline 5C and 7A at Pohang Accelerator Laboratory (PAL) in South Korea. \\\\({}^{\\\\rm b}R_{\\\\rm range}=\\\\sum_{k}\\\\sum_{i}\\\\left|\\\\ {\\\\rm I}\\\\left\\\\{ \\\\left\\\\{ \\\\left\\\\{ \\\\left\\\\{ \\\\left\\\\{ \\\\left\\\\{ \\\\left\\\\{ \\\\left\\\\{ \\\\left\\\\{ \\\\left\\\\{ \\\\left\\\\} \\\\right\\\\} \\\\} \\\\right\\\\} \\\\right\\\\} \\\\right\\\\} \\\\right\\\\} \\\\right\\\\} \\\\right\\\\} \\\\right.\\n\\n'"}